HI
RPRX icon

Humankind Investments’s Royalty Pharma RPRX Stock Holding History

Humankind Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,162
Closed -$294K – 142
2023
Q1 		$294K Buy
8,162
+966
+13% +$35.8K 0.12% 90
2022
Q4 		$284K Buy
7,196
+234
+3% +$9.77K 0.12% 93
2022
Q3 		$280K Buy
6,962
+460
+7% +$19.6K 0.14% 87
2022
Q2 		$273K Sell
6,502
-184
-3% -$7.54K 0.13% 83
2022
Q1 		$260K Buy
6,686
+564
+9% +$22.1K 0.11% 97
2021
Q4 		$244K Buy
6,122
+269
+5% +$10.4K 0.1% 103
2021
Q3 		$212K Buy
+5,853
New +$227K 0.1% 102

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Humankind Investments's RPRX Position: Q2 2023 in Review

Humankind Investments sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 8,162 shares — an estimated $294K sold.

Humankind Investments first reported a position in RPRX in Q3 2021 and held it in 7 quarters. The position peaked at $294K in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

  • Humankind Investments reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
  • Humankind Investments sold 8,162 Royalty Pharma shares in Q2 2023, an estimated $294K.
  • Humankind Investments first reported a position in Royalty Pharma in Q3 2021 and held it in 7 quarters.
  • Humankind Investments's Royalty Pharma position peaked at $294K in Q1 2023.
  • 325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Humankind Investments's 13F filing for Q2 2023, filed 9 Aug 2023.